Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elisabeth M. TenVergert is active.

Publication


Featured researches published by Elisabeth M. TenVergert.


American Journal of Transplantation | 2007

Efficacy and safety of antifibrinolytic drugs in liver transplantation: A systematic review and meta-analysis

Iq Molenaar; Nienke Warnaar; Harry J.M. Groen; Elisabeth M. TenVergert; Maarten J. H. Slooff; Robert J. Porte

Although several randomized controlled trials (RCTs) have shown the efficacy of antifibrinolytic drugs in liver transplantation, their use remains debated due to concern for thromboembolic complications. None of the reported RCTs has shown a higher incidence of these complications in treated patients; however, none of the individual studies has been large enough to elucidate this issue completely. We therefore performed a systematic review and meta‐analysis of efficacy and safety endpoints in all published controlled clinical trials on the use of antifibrinolytic drugs in liver transplantation.


Health and Quality of Life Outcomes | 2010

TMD pain: the effect on health related quality of life and the influence of pain duration

Geerten-Has Tjakkes; Jan-Jaap Reinders; Elisabeth M. TenVergert; Boudewijn Stegenga

ObjectivesAs impact of literature concerning this subject is scarce, the objectives of this study were to assess whether the Health Related Quality of Life (HRQoL) is decreased in patients with painful temporomandibular disorders as compared to the HRQoL in the general population, and to evaluate to what extent pain duration affects HRQoL.MethodsData concerning physical and mental health were retrieved from patients with painful temporomandibular disorders. Assessment tools used were: the Mandibular Function Impairment Questionnaire (MFIQ), the Short-Form-36 (SF-36), the Hospital Anxiety and Depression Schedule (HADS), and the General Health Questionnaire (GHQ). In order to examine the influence of the duration of pain on HRQoL, the total sample was divided into three different subgroups. Subgroup 1 consisted of patients with complaints existing less than one year. Patients with complaints from 1 to 3 years were allocated to the second group. The 3rd subgroup included patients with complaints longer than 3 years.ResultsThe total sample consisted of 95 patients (90 females and 5 males). On most physical and social functioning items, groups 2 and 3 scored significantly worse than the general population. On the other hand, none of the groups differed from the general population when comparing the mental items. Duration of pain was significantly correlated with SF-36 subscale physical functioning and the mandibular impairment.ConclusionPatients with TMD pain less than one year score better than compared to the population norm. With a longer duration of pain, mental health scores and role limitations due to emotional problems do not appear to be seriously affected by reduced physical health, while social functioning appears to be considerably affected.


Annals of Surgery | 2002

Graft Loss After Pediatric Liver Transplantation

Paul M. J. G. Peeters; Elisabeth M. TenVergert; Koert P. de Jong; Robert J. Porte; Jh Zwaveling; Charles M. A. Bijleveld; Annette S. H. Gouw; Maarten J. H. Slooff

ObjectiveTo describe the epidemiology and causes of graft loss after pediatric liver transplantation and to identify risk factors. Summary Background DataGraft failure after transplantation remains an important problem. It results in patient death or retransplantation, resulting in lower survival rates. MethodsA series of 157 transplantations in 120 children was analyzed. Graft loss was categorized as early (within 1 month) and late (after 1 month). Risk factors were identified by analyzing recipient, donor, and transplantation variables. ResultsKaplan-Meier 1-month and 1-, 3-, and 5-year patient survival rates were 85%, 82%, 77%, and 71%, respectively. Graft survival rates were 71%, 64%, 59%, and 53%, respectively. Seventy-one of 157 grafts (45%) were lost: 18 (25%) by death of patients with functioning grafts and 53 (75%) by graft-related complications. Forty-five grafts (63%) were lost early after transplantation. Main causes of early loss were vascular complications, primary nonfunction, and patient death. Main cause of late graft loss was fibrosis/cirrhosis, mainly as a result of biliary complications or unknown causes. Child-Pugh score, anhepatic phase, and urgent transplantation were risk factors for early loss. Donor age, donor/recipient weight ratio, blood loss, and technical-variant liver grafts were risk factors for late loss. ConclusionsTo prevent graft loss after pediatric liver transplantation, potential recipients should be referred early so they can be transplanted in an earlier phase of their disease. Technical-variant liver grafts are risk factors for graft survival. The logistics of the operation need to be optimized to minimize the length of the anhepatic phase.


Transplantation | 2001

Retransplantation of the liver in children

Paul M. J. G. Peeters; Elisabeth M. TenVergert; Koert P. de Jong; Robert J. Porte; Jh Zwaveling; Charles M. A. Bijleveld; Maarten J. H. Slooff

Background. Because of the poor outcome of hepatic retransplantation, it is still debated whether this procedure should be performed in an era of donor organ scarcity. The aim of this study was to analyze outcome of hepatic retransplantation in children, to identify risk factors influencing this outcome, and to assess morbidity and causes of death. Methods. A series of 97 children after a single transplantation and 34 children with one retransplantation was analyzed. Results. The 1-, 3-, and 5-year survival of children with a retransplantation was 70, 63, and 52%, respectively, compared with 85, 82, and 78%, respectively, for children after a single transplantation (P =0.009). Survival of children with a retransplantation within 1 month after primary transplantation was worse (P =0.007) and survival of children with a late retransplantation was comparable (P =0.66) with single transplantation. In early retransplantations, the Child-Pugh score was higher, donors were older and weighed more, and more technical variant liver grafts were used compared with single transplantations. Biliary atresia and a high Child-Pugh score were associated with decreased patient survival after retransplantation. Sepsis was the most important complication and cause of death after retransplantation. Conclusions. Retransplantation is a significant event after pediatric liver transplantation. Outcome after hepatic retransplantation in children is inferior compared with single transplantation. This difference is explained by low survival after early retransplantation and can be explained by the poor clinical condition of the children at time of retransplantation, especially in children with biliary atresia, and by the predominant use of technical variant liver grafts in retransplantations.


Clinical Transplantation | 2004

The effect of bronchiolitis obliterans syndrome on health related quality of life

Karin M. Vermeulen; Henk Groen; Wim van der Bij; Michiel E. Erasmus; Gerard H. Koëter; Elisabeth M. TenVergert

Abstract:  Bronchiolitis obliterans syndrome (BOS) is the most important factor limiting long‐term survival after lung transplantation, and has a substantial impact on patients‘ daily life in terms of disability and morbidity. Aim of our study was to examine the effects of BOS on health related quality of life (HRQL) in lung transplantation patients. Data on HRQL from 29 patients who developed BOS at least 18 months earlier were studied longitudinally. HRQL measures were: the Nottingham Health Profile (NHP), the State Trait Anxiety Inventory (STAI), the Self‐rating Depression Scale (ZUNG), and the Index of Well Being (IWB). Furthermore questions concerning activities of daily life and dyspnea were asked. The majority of the patients were male, and the most common diagnosis was emphysema. After the onset of BOS, significantly more restrictions were reported on the dimensions energy and mobility of the NHP. These restrictions appeared to increase over time. After the onset of BOS, STAI scores remained more or less stable and close to the value of the general population. ZUNG scores were significantly higher after the onset of BOS, and patients experienced a lower level of well being than the general population. The percentage of patients that reported to be able to perform activities of daily life without effort declined dramatically after the onset of BOS. Furthermore, the percentage of patients complaining of dyspnea increased after the onset of BOS. In conclusion, our study showed that HRQL was negatively affected by the onset of BOS. However, in spite of these less favorable long‐term results, even patients who develop BOS may at least temporarily benefit from a lung transplantation.


Transplantation | 2000

Predictive factors for portal fibrosis in pediatric liver transplant recipients

Paul M. J. G. Peeters; Marius C. van den Heuvel; Charles M. A. Bijleveld; Koert P. de Jong; Elisabeth M. TenVergert; Maarten J. H. Slooff; Annette S. H. Gouw

Background. Recent histopathological studies showed an unexpected high incidence of pathological changes in asymptomatic survivors after pediatric liver transplantation. The aim of this study was to analyze the occurrence of histological abnormalities, to assess the clinical significance, and to identify predictive factors for these pathological changes. Methods. The first annual protocol graft biopsies of 84 consecutive liver transplants were analyzed and correlated with concomitant liver function tests. Identification of predictive factors for the histological abnormalities in the biopsies was performed by a multivariate logistic regression analysis. Results. The incidence of portal fibrosis (PF) was 31%. Liver function tests showed except for the albumin level, an increase in the PF group compared with the group without PF. Mean values of alkaline phosphatase and direct bilirubin were 264 U/liter and 3 &mgr;mol/liter, respectively, in the normal group, and 435 U/liter and 23 &mgr;mol/liter, respectively, in the PF group (P =0.043 and 0.037). Eight of 19 univariantly tested variables were entered into a logistic regression model: cold ischemia time, preservation solution, type of allograft, cytomegalovirus recipient status, type of biliary reconstruction, biliary complications, graft complications, and rejection. A significant positive correlation with PF was found for cold ischemia time, biliary complications, and cytomegalovirus status. Acute rejection showed a negative correlation. Conclusions. The incidence of PF within 1 year post liver transplantation was 31%. This finding was accompanied by cholestatic liver function test abnormalities. Factors predisposing to PF were a prolonged cold ischemia time, biliary complications, and a positive cytomegalovirus recipient status. Acute rejection seemed to prevent for PF.


Health Economics | 1997

Lifetime costs of lung transplantation: Estimation of incremental costs

Petra J. van Enckevort; Marc A. Koopmanschap; Elisabeth M. TenVergert; Albert Geertsma; Wim van der Bij; Wim J. de Boer; Frans Rutten

Despite an expanding number of centres which provide lung transplantation, information about the incremental costs of lung transplantation is scarce. From 1991 until 1995, in The Netherlands a technology assessment was performed which provided information about the incremental costs of lung transplantation. Costs in the situation with and without a transplantation programme were compared from a lifetime perspective. Because randomization was ethically inadmissible, only costs in the situation with the programme were observed. Both conventional treatment costs and costs of the transplantation programme were registered. Costs in the situation without the programme were based on the conventional treatment costs in the situation with the programme. Due to the study period of four years, long term follow-up costs were estimated. The total incremental costs per transplanted patient were estimated at Dfl 466,767 (5% discounted costs). The main part of these costs was caused by the high costs during the lifetime follow-up of the patients.


Medical Care Research and Review | 2009

Cost of liver transplantation: a systematic review and meta-analysis comparing the United States with other OECD countries.

Christian S. van der Hilst; Alexander J. C. IJtsma; Maarten J. H. Slooff; Elisabeth M. TenVergert

Large cost variations of liver transplantation are reported. The aim of this study was to assess cost differences of liver transplantation and clinical follow-up between the United States and other Organization for Economic Cooperation and Development (OECD) countries. Eight electronic databases were searched, and 2,000 citations published after 1990 with more than 10 transplantations, and with original cost data, were identified. A total of 30 articles included 5,975 liver transplantations. Meta-analysis was used to derive a combined mean using a random-effects model to test for heterogeneity between studies. Estimated mean cost of a U.S. liver transplantation was US


Transplant International | 2005

Stress, psychological distress, and coping in patients on the waiting list for lung transplantation: an exploratory study

Karin M. Vermeulen; Otto H. Bosma; Wim van der Bij; Gerard H. Koëter; Elisabeth M. TenVergert

163,438 (US


Journal of Heart and Lung Transplantation | 2008

Pre-transplant quality of life does not predict survival after lung transplantation

Karin M. Vermeulen; Elisabeth M. TenVergert; Erik Verschuuren; Michiel E. Erasmus; Wim van der Bij

145,277-181,598) compared to US

Collaboration


Dive into the Elisabeth M. TenVergert's collaboration.

Top Co-Authors

Avatar

Maarten J. H. Slooff

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Robert J. Porte

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Karin M. Vermeulen

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Wim van der Bij

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Koert P. de Jong

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Annette S. H. Gouw

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Christian S. van der Hilst

University Medical Center Groningen

View shared research outputs
Top Co-Authors

Avatar

Gerard H. Koëter

University Medical Center Groningen

View shared research outputs
Researchain Logo
Decentralizing Knowledge